HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic
Auf einen Blick
- Projektleiter/in : Prof. Dr. Rainer Riedl
- Projektteam : Dr. Mark Sephton, Patrik Züger
- Projektvolumen : CHF 1'382'297
- Projektstatus : abgeschlossen
- Drittmittelgeber : KTI (KTI-Projekt)
- Projektpartner : BioVersys AG
- Kontaktperson : Rainer Riedl
Beschreibung
A new and highly innovative treatment will be realized by a novel and patentable orally available small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic bacterial strains.